Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
Status:
RECRUITING
Trial end date:
2028-02-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.
Phase:
PHASE2
Details
Lead Sponsor:
Ann & Robert H Lurie Children's Hospital of Chicago